Preclinical drug development: rationale and methods
Venditti, J.M.
Seminars in Oncology 8(4): 349-361
1981
ISSN/ISBN: 0093-7754 PMID: 7323809 Document Number: 174955
Document emailed within 1 workday
Related Documents
Danhof, M.; Visser, S.A. G. 2002: Pharmaco-electroencephalography and pharmacokinetic-pharmacodynamic modeling in drug development: focus on preclinical steps Methods and Findings in Experimental and Clinical Pharmacology 24 Suppl D: 127-128Korstanje, C. 2003: Integrated assessment of preclinical data: shifting high attrition rates to earlier phase drug development Current Opinion in Investigational Drugs 4(5): 519-521
Sun, D.; Yu, L.X.; Hussain, M.A.; Wall, D.A.; Smith, R.L.; Amidon, G.L. 2004: In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome Current Opinion in Drug Discovery and Development 7(1): 75-85
Bornschein, M.; Hoffmann, K.; Voigt, R. 1985: Development and present status of methods for the determination of in vitro drug availability of suppositories Die Pharmazie 40(7): 449-455
Boyd, M.A.; Wood, W.W.; Conry, R.F. 1980: Prediction of preclinical operative dentistry performance in two instructional methods Journal of Dental Education 44(6): 328-331
Hashimoto, K. 2003: Preclinical evaluation of drug induced QT prolongation Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 121(6): 408-410
Furukawa, T. 1996: Yawning behavior for preclinical drug evaluation Methods and Findings in Experimental and Clinical Pharmacology 18(2): 141-155
Cushion, M.T.; Walzer, P.D. 2009: Preclinical drug discovery for new anti-pneumocystis compounds Current Medicinal Chemistry 16(20): 2514-2530
Mcguire, J.L.; Hahn, D.W.; Philipps, A. 1985: Preclinical research and development of norethisterone Contraception Fertilite Sexualite 13(1 Suppl): 437-444
Zarnke, K.B.; Campbell, N.R.; McAlister, F.A.; Levine, M. 2000: A novel process for updating recommendations for managing hypertension: rationale and methods Canadian Journal of Cardiology 16(9): 1094-1102
Löwik, M.R.; Brants, H.A.; Brussaard, J.H.; van den Berg, H.; Kistemaker, C.; Hermus, R.J. 1997: Rationale, design and methods of a study on micronutrient status among adults European Journal of Clinical Nutrition 51(Suppl 3): S4-11
Naryshkin, A.G.; Preobrazhenskaia, I.G.; Timofeev, I.S.; Filimonov, V.N.; Sheliakin, A.M. 2000: The new pathogenetic treatment of cervical dystonia: rationale, methods, outcomes Zhurnal Voprosy Neirokhirurgii Imeni N. N. Burdenko 3: 7
Osieka, R. 1984: Human malignant melanoma: preclinical and clinical drug evaluation Behring Institute Mitteilungen 74: 353-367
Shipulina, Z.V.; Tepikina, L.A.; Kartashova, A.V. 1993: Rationale for maximum permissible concentration and methods for determination of trichloroacetaldehyde in atmospheric air Gigiena i Sanitariia 10: 6-7
Wannamaker, J.L.; Bender, A.P.; Muckala, K.A. 1982: Population-based studies of diabetes mellitus in Minnesota: rationale and methods Minnesota Medicine 65(7): 429-431
Salvetti, A.; Virdis, A.; Di Venanzio, L. 1993: The rationale for drug combinations in the therapy of arterial hypertension Annali Italiani di Medicina Interna: Organo Ufficiale Della Societa Italiana di Medicina Interna 8 Suppl: 107s-110s
Gonschior, P.; Wilensky, R.; March, K.; Höfling, B. 1996: Local drug administration systems, preclinical and clinical use: perspectives and limitations Zeitschrift für Kardiologie 85(3): 155-165
Whitehouse, P.J.; Sciulli, C.G.; Mason, R.M. 1997: Dementia drug development: use of information systems to harmonize global drug development Psychopharmacology Bulletin 33(1): 129-133
Drukin, E.Ia. 1975: Lung cancer discovered in the preclinical phase of development Voprosy Onkologii 21(4): 51-55
Chekman, I.S.; Tkachuk, V.V. 1984: Principles, methods and criteria for assessing the effectiveness of potentially cardiotonic compounds at the preclinical research stage Farmakologiia i Toksikologiia 47(6): 5-15